Mephenytoin hydroxylation deficiency: kinetics after repeated doses
- PMID: 6690169
- DOI: 10.1038/clpt.1984.5
Mephenytoin hydroxylation deficiency: kinetics after repeated doses
Abstract
Deficient aromatic hydroxylation of S-mephenytoin was observed in an index subject during a kinetic study of stereoselective metabolism of mephenytoin. A genetic basis for this defect was suggested by decreased urinary recovery of 3-methyl-5-(4-hydroxyphenyl)-5-ethylhydantoin (4-OH-M) in the 24 hr after oral racemic mephenytoin in two brothers of the propositus. The parents and a third brother had urinary recoveries of 4-OH-M of the same order as in a group of 20 normal subjects. The kinetic implications of this defect were studied in the index subject and compared with four normal subjects after a single oral dose of differentially radiolabeled pseudoracemic mephenytoin (5 microCi of 14C-S-mephenytoin, 45 microCi of H3-R-mephenytoin, and 11.5 mumol/kg of both S- and R-mephenytoin) followed by single oral doses of 1.4 mmol of unlabeled racemic mephenytoin daily the next 4 days. In normal subjects, there was substrate stereoselective metabolism with the S-enantiomer rapidly excreted as 4-OH-M and the R-enantiomer slowly excreted as 5-phenyl-5-ethylhydantoin (PEH). Stereoselective metabolism persisted during repeated dosing. In the hydroxylation-deficient subject, there was no evidence of stereoselective metabolism, recovery of 4-OH-M was low, and both enantiomers were slowly excreted, predominantly as PEH. Plasma PEH concentrations and urinary PEH excretion rates were approximately twice that in normal subjects. Thus a genetic deficiency in ability to hydroxylate S-mephenytoin results in the S-enantiomer metabolization by the alternate route of demethylation to PEH that cumulates, thereby, in comparison to the normal, effectively doubling the dose of total hydantoin.
Similar articles
-
Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.J Pharmacol Exp Ther. 1984 Jul;230(1):28-33. J Pharmacol Exp Ther. 1984. PMID: 6747829
-
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.J Pharmacol Exp Ther. 1985 Sep;234(3):662-9. J Pharmacol Exp Ther. 1985. PMID: 4032286
-
Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man.Epilepsia. 1984 Feb;25(1):1-7. doi: 10.1111/j.1528-1157.1984.tb04148.x. Epilepsia. 1984. PMID: 6420144
-
Genetic polymorphism of S-mephenytoin hydroxylation.Pharmacol Ther. 1989;43(1):53-76. doi: 10.1016/0163-7258(89)90047-8. Pharmacol Ther. 1989. PMID: 2675129 Review. No abstract available.
-
Genetic polymorphism of S-mephenytoin 4'-hydroxylation.Psychopharmacol Bull. 1996;32(2):219-30. Psychopharmacol Bull. 1996. PMID: 8783891 Review.
Cited by
-
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.Br J Clin Pharmacol. 1989 May;27(5):620-5. doi: 10.1111/j.1365-2125.1989.tb03426.x. Br J Clin Pharmacol. 1989. PMID: 2757884 Free PMC article.
-
The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.Br J Clin Pharmacol. 1998 Jan;45(1):27-9. doi: 10.1046/j.1365-2125.1998.00643.x. Br J Clin Pharmacol. 1998. PMID: 9489590 Free PMC article.
-
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.Eur J Clin Pharmacol. 1984;26(6):753-9. doi: 10.1007/BF00541938. Eur J Clin Pharmacol. 1984. PMID: 6489416
-
Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.Br J Clin Pharmacol. 1991 Mar;31(3):350-2. doi: 10.1111/j.1365-2125.1991.tb05542.x. Br J Clin Pharmacol. 1991. PMID: 2054275 Free PMC article.
-
Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern Oriental subjects.Br J Clin Pharmacol. 1992 Jun;33(6):665-6. Br J Clin Pharmacol. 1992. PMID: 1389943 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources